Clinical trial
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of…
NCT00000626 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000626 |
|---|---|
| Title | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease |
| Official title | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride |
| Enrollment | 27 |
| Completion | Feb 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 27, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: